Matthew Child

Title: Innovations of Matthew Child in Gene Therapy

Introduction

Matthew Child is an accomplished inventor based in Ashland, MA (US). He has made significant contributions to the field of gene therapy, particularly in the development of adeno-associated virus (AAV) capsids. His work focuses on enhancing the delivery of therapeutic agents to target tissues, which is crucial for effective treatment.

Latest Patents

Matthew Child holds 1 patent related to his innovative work. His patent, titled "AAV capsids with increased tropism to brain tissue," discloses compositions, methods, and processes for the preparation, use, and formulation of adeno-associated virus capsid proteins. These capsid proteins include targeting peptide inserts that enhance their tropism to specific target tissues, particularly brain tissue.

Career Highlights

Matthew Child is currently employed at Voyager Therapeutics, Inc., where he continues to advance his research in gene therapy. His expertise in AAV technology has positioned him as a key figure in the development of novel therapeutic strategies.

Collaborations

Throughout his career, Matthew has collaborated with notable colleagues, including Mathieu E Nonnenmacher and Jinzhao Hou. These collaborations have further enriched his research and contributed to the advancement of gene therapy technologies.

Conclusion

Matthew Child's innovative work in the field of gene therapy, particularly with AAV capsids, showcases his commitment to improving therapeutic delivery systems. His contributions are paving the way for more effective treatments for various neurological conditions.